The present invention relates to crystal modifications of racemic (2R,S)- and enantiomerically pure (2R)-resp. (2S)-DOTAP chloride, to processes for the preparation thereof, and to the use thereof for the preparation of pharmaceutical compositions.
本发明涉及外消旋(2R,S)-和对映体纯(2R)-对应(2S)-DOTAP
氯化物的晶体改性,涉及其制备工艺以及用于制备药物组合物。